Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine

Acute myeloid leukemia (AML) patients display dismal prognosis due to high prevalence of refractory and relapsed disease resulting from chemoresistance. Treatment protocols, primarily based on the anchor drug Cytarabine, remained chiefly unchanged in the past 50 years with no standardized salvage re...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, May, Stark, Michal, Berman, Bluma, Assaraf, Yehuda G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525253/
https://www.ncbi.nlm.nih.gov/pubmed/31101804
http://dx.doi.org/10.1038/s41419-019-1626-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525253/
https://www.ncbi.nlm.nih.gov/pubmed/31101804
http://dx.doi.org/10.1038/s41419-019-1626-x

Ejemplares similares